Recombinant Mouse Anti-PfCyRPA Antibody (c12) (CAT#: PABC-392)

Figure 1 Anti-PfCyRPA and anti-PFRH5 mAbs have both in vitro and in vivo an additive inhibitory effect on parasite growth.

(A) Growth inhibition in vitro. Synchronized P. falciparum 3D7 blood-stage parasites were cultured for one cycle of merozoite invasion in the presence of anti-PfCyRPA c12 mAb, anti-PFRH5 BS1.2 mAb, and their combinations. Thed NR4.2 mAb was used as negative control, inhibitory and non-inhibitory anti-MSP-1 mAbs (12.10 and 2F10, respectively) were used as reference. Percent parasite growth inhibition was calculated against the parasitemia of PBS control wells. (B) Growth inhibition in vivo. NODscidIL2Rynull mice received purified anti-PfCyRPA c12 mAb and/or anti-PfRH5 BS1.2 mAb and were then infected with P falciparum 3D7 and parasitemia was monitored over 6 days. Values represent the mean parasitemia in human erythrocytes in peripheral blood of three mice per group. PBS and an unrelated control mAb were used as negative control.

Favuzza, P., Guffart, E., Tamborrini, M., Scherer, B., Dreyer, A. M., Rufer, A. C., ... & Gsell, B. (2017). Structure of the malaria vaccine candidate antigen CyRPA and its complex with a parasite invasion inhibitory antibody. Elife, 6, e20383.